<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Angiotensinogen (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AGT</z:e>) and plasminogen activator inhibitor-1 (PAI-1) are expressed in both vascular and adipose tissues </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="2719,48432">Angiotensin II</z:chebi> (AG II) has an adipogenic effect and increases PAI-1 expression </plain></SENT>
<SENT sid="2" pm="."><plain>To evaluate the <z:hpo ids='HP_0011010'>chronic</z:hpo> effects of AG II type 1 receptor (AT(1)R) antagonism on adipose mass and PAI-1 expression in vascular and adipose tissues, <z:chebi fb="0" ids="6541">losartan</z:chebi> (30mg/kg/day) was administered to Otsuka Long-Evans Tokushima Fatty (OLETF) rats, a model of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, for 20 weeks </plain></SENT>
<SENT sid="3" pm="."><plain>Adipose mass and regional fat distribution in the abdomen did not change after <z:hpo ids='HP_0011010'>chronic</z:hpo> AT(1)R antagonism in OLETF rats </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AGT</z:e> and PAI-1 mRNA expressions in adipose tissue of OLETF rats were significantly increased compared with Long-Evans Tokushima Otsuka (LETO) rats, the <z:mpath ids='MPATH_458'>normal</z:mpath> control </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0011010'>Chronic</z:hpo> <z:chebi fb="0" ids="6541">losartan</z:chebi> therapy further increased the level of adipose <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AGT</z:e> in OLETF rats, but did not affect the level of adipose PAI-1 mRNA </plain></SENT>
<SENT sid="6" pm="."><plain>In contrast, aortic PAI-1 expression in OLETF rats was attenuated by <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:chebi fb="0" ids="6541">losartan</z:chebi> therapy </plain></SENT>
<SENT sid="7" pm="."><plain>Our results have two implications </plain></SENT>
<SENT sid="8" pm="."><plain>First, adipose tissue may be an important source of AG II in <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> even after <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:chebi fb="0" ids="6541">losartan</z:chebi> therapy </plain></SENT>
<SENT sid="9" pm="."><plain>Second, <z:hpo ids='HP_0011010'>chronic</z:hpo> AT(1)R antagonism with <z:chebi fb="0" ids="6541">losartan</z:chebi> causes differential effects on vascular and adipose PAI-1 expression </plain></SENT>
</text></document>